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exists in terms of laboratory monitoring protocols and perceived
barriers regarding the use of these drugs.
PAR8
ALTERNATIVE DECISION ANALYSIS MODELING IN THE
ECONOMIC EVALUATION OF TUMOR NECROSIS 
FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID
ARTHRITIS
Kamal KM, Miller LA, Madhavan SM, Kavookjian J
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To provide a review of the decision analytic
models used in the economic evaluations of Tumor Necrosis
Factor (TNF) inhibitors (adalimumab, etanercept, and inﬂix-
imab) in Rheumatoid Arthritis (RA) and to address some impor-
tant issues surrounding the choice of such analytic modeling
techniques in these economic analyses. METHODS: A system-
atic literature search was conducted by one researcher among
publications in peer-reviewed journals from January, 1996 to
October, 2004 through MEDLINE and EMBASE databases to
identify studies that used decision analysis models to evaluate
cost-effectiveness of TNF inhibitors in patients with RA. All the
studies of TNF inhibitors in patients other than RA, and those
conducted in children were excluded from the review. RESULTS:
The systematic literature search identiﬁed 28 articles. Of these
only ten studies fulﬁlled the inclusion criteria and were included
in the review process. These ten studies used different decision
analysis models, which are listed as follows: decision trees (two
studies), Markov model (four studies), Monte Carlo Simulation
(two studies), and Discrete Event Simulation (two studies). 
Since the models vary in complexity, the choice of these model-
ing techniques depends on the course of the disease, impact of
the drugs, and the availability of data. The results of most of the
studies indicate that all three TNF inhibitors are cost-effective
compared with traditional agents and have cost-effectiveness
ratios of less than $50,000/QALY gained. However, one study
reports the cost-effectiveness ratio of more than $100,000/QALY
for etanercept and inﬂiximab. CONCLUSION: Based on the
results derived from different modeling techniques, it would
seem that all methods provide useful techniques for economic
evaluations of TNF inhibitors. However, to increase the conﬁ-
dence of the physicians and payers, key issues such as validity of
the models, transparency during construction of the models,
quality of data sources, and handling of uncertainty need to be
resolved.
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OBJECTIVES: In patients with long-standing, severe RA who
failed methotrexate (MTX), we sought to determine whether
monotherapy with the fully human, anti-TNF monoclonal anti-
body, adalimumab, improved two important patient-reported
outcomes (health utility and fatigue) vs. placebo. METHODS:
The Health Utilities Index Mark 3 (HUI3) and the Functional
Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) ques-
tionnaire were administered in a health economics companion
study to a placebo-controlled, pivotal trial (DE011) of adali-
mumab monotherapy. HUI3 and FACIT-F were administered 
at baseline, three-months, and end of study. The HUI3 scale is
0–1, with “1” denoting perfect health and “0” denoting death.
FACIT-F scores range from 0–52, with higher scores represent-
ing less fatigue. Changes in HUI3 of >=0.03 and FACIT-F of >=4
are considered clinically meaningful. RESULTS: Patients received
either adalimumab 40mg every other week without concomitant
disease-modifying antirheumatic (DMARD) therapies (n = 99) or
placebo (n = 96) over 26-weeks. Baseline characteristics were
indicative of long-standing, severe RA: age: 53yrs; disease dura-
tion: 11yrs; TJC (0–68): 34; HAQ: 1.9, CRP (mg/L): 56.6; pre-
vious DMARDs: four (mean values). Baseline utility scores were
comparable for adalimumab and placebo (0.27 vs. 0.28), and
much worse than that of the age- and sex-adjusted population
norm (0.88). Similarly, baseline FACIT-F scores were also com-
parable (26.1 for adalimumab and 26.3 for placebo) and, again,
considerably worse than that of the general population (43.6).
After 26-weeks, mean HUI3 scores increased 0.18 from baseline
for adalimumab vs. 0.08 for placebo (p < 0.05). Mean FACIT-F
scores increased 8.7 for adalimumab vs. 3.3 for placebo (p <
0.01). CONCLUSION: Although optimal use of tumor necrosis
factor antagonists is with MTX, some patients do not tolerate
or beneﬁt from MTX. Adalimumab monotherapy provided 
statistically signiﬁcant, clinically meaningful improvements in
health utility and fatigue for patients with severe, long-standing
RA who had failed MTX therapy.
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OBJECTIVES: Patient satisfaction with medication is increas-
ingly set as treatment goal because it is hypothesized to increase
compliance. This study investigates plausible associations be-
tween levels of satisfaction with pain medication and external
variables (e.g., satisfaction with medication information, med-
ication characteristics, treatment efﬁcacy as perceived by the
patient) as established in the literature; to explore the effect of
satisfaction with pain medication on intention to comply with
current medication. METHODS: Rheumatoid arthritis (RA)
patients undergoing treatment were mailed two sets of ques-
tionnaires two-weeks apart: The Pain Treatment Satisfaction
Scale, the SF-36, a pain visual analogue scale, and the Brief Pain
Inventory. The inﬂuence of these variables on satisfaction with
pain medication was estimated using structural equation model-
ing. RESULTS: The population consisted of 68 RA patients with
a mean baseline pain score on a one to ten scale of 4.73 ± 2.72.
The overall model was signiﬁcant (chi-square p-value <0.001)
with an excellent ﬁt (normed ﬁt index = 0.97). The strongest
observed relationship was a positive association between satis-
faction with pain medication and intention to take pain med-
ication (unstandardized path coefﬁcient Beta = 0.54, p < 0.001).
Predictors of satisfaction with pain medication included duration
of pain relief (Beta = 0.45, p < 0.001), satisfaction with the infor-
mation provided by health care professionals (Beta = 0.21, p <
0.01) and expectations of pain relief (Beta = 0.20, p < 0.01).
CONCLUSION: RA patients’ intention to comply with pain
medication is inﬂuenced to a large extent by the level of satis-
faction with their pain medication. Duration of pain relief posi-
tively inﬂuences satisfaction with pain medication, as do (to a
lesser degree) satisfaction with information about treatment and
medication expectations. Improving compliance with care not
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only depends on the clinical effectiveness of medications, but also
on how satisﬁed patients are with treatment information and
how well their treatment expectations are managed.
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THE IMPACT OF DEPRESSION ON RHEUMATOID ARTHRITIS
PATIENT QUALITY OF LIFE
Zhang L, Nichol MB
University of Southern California, School of Pharmacy, Los Angeles,
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OBJECTIVES: The presence of psychological distress, such as
depression and negative mood is very common in patients with
rheumatoid arthritis (RA). The purpose of this study was to
examine the impact of depression on RA patients’ quality of life.
METHODS: The study consisted of 1130 rheumatoid arthritic
patients from a Western US managed care organization. Longi-
tudinal data on diagnosis and quality of life was collected at
three annual periods. Patients’ health related quality of life was
measured by the Physical Component Summary (PCS) score
from the SF-36 as rheumatoid arthritis is generally considered a
disease with physical impairment. We derived the effect size in
order to compare the quality of life between the depressed 
and the non-depressed RA patients. A dynamic panel data model
was further developed to examine the impact of depression on
patients’ quality of life. The model contained the lagged depen-
dent variable (quality of life of the previous year). Other covari-
ates included in the model were demographic variables and
disease severity, as measured by Chronic Disease Score (CDS).
RESULTS: The incidence of depression in RA patients increased
from 10.18% to 14.42% over the study period. The effect size
of PCS fell into the medium category (0.5–0.8). The effect size
increased with time, indicating that the difference of quality of
life between the depressed and non-depressed RA patients
increases with the disease duration. Regression analysis from the
Panel data model revealed that depression had signiﬁcant effect
on RA patients’ quality of life after controlling for demographic
variables and disease severity (P < 0.01). CONCLUSIONS:
Depression in patients with rheumatoid arthritis can signiﬁcantly
affect their perceived quality of life. This result suggested that
patient intervention related to change patients’ coping style, or
illness conceptions should be encouraged.
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ABATACEPT (CTLA4IG) IN COMBINATION WITH
METHOTREXATE DEMONSTRATES SUSTAINED
IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER
TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH
INADEQUATE RESPONSE TO METHOTREXATE
Li T, Maclean R, Nuamah I, Becker J
Bristol-Myers Squibb, Princeton, NJ, USA
OBJECTIVES: Abatacept (CTLA4Ig) is the ﬁrst in a new class
of agents for the treatment of RA that selectively modulates 
the co-stimulatory signal required for full T-cell activation, 
has shown good and efﬁcacy and tolerability during in a one-
year, double-blind, placebo-controlled trial of Abatacept in
methotrexate (MTX) inadequate responders. This analysis
examined the long-term effect of Abatacept on patient-reported
outcomes (PRO) in an open-label extension of this study at two-
years. METHODS: In the blinded phase of the study, patients
with active RA despite MTX treatment were randomized to
receive Abatacept 10mg/kg IV monthly + MTX or placebo +
MTX for one-year. Patients who completed the blinded phase
were eligible to enroll in the long-term extension during which
patients were treated with a ﬁxed dose of Abatacept 10mg/kg.
Patients evaluated pain and disease activity using the Visual
Analog Scale (VAS), physical function using the modiﬁed Health
Assessment Questionnaire (mHAQ), and QOL using the SF-36.
RESULTS: In total, 115 patients were randomized to the 
Abatacept + MTX group; 84 patients (73%) entered the LTE and
75 (89%) of these patients completed two-years of treatment.
Statistically signiﬁcant improvements from baseline in pain,
disease activity, and physical function were reported by 
Abatacept-treated patients as early as day 15, and were further
improved and maintained during two-years of treatment. The
improvements in patient reported outcomes preceded the
improvement seen in the overall clinical response measured by
the American College of Rheumatology criterion for a 50%
improvement. Abatacept also sustained signiﬁcant improvements
in all eight domains of the SF-36, with the greatest improvements
seen in physical function, role-physical, bodily pain, vitality and
social function domains. CONCLUSIONS: Abatacept rapidly
and signiﬁcantly improves patient-reported outcomes and these
improvements are sustained during two-years of treatment.
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META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF
SCREENING TESTS FOR COLORECTAL CANCER
Slivinskas JC1, Gagnon YM1, Levy AR2, Enns RA3
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OBJECTIVES: To conduct a meta-analysis on the diagnostic
accuracy of ﬁve screening tests for colorectal cancer (CRC):
faecal occult blood test (FOBT), double-contrast barium 
enema (DCBE), ﬂexible sigmoidoscopy (FSIG), conventional
colonoscopy (COL) and computed tomography colonoscopy
(CTCOL). METHODS: A literature search was carried out 
in MEDLINE (1966–2004) for each of the ﬁve tests. Articles
were reviewed by two independent reviewers according to the
Berkeley Systematic Reviews guidelines. Inclusion criteria were:
1) RCTs or observational studies of screening methods for CRC;
2) subjects patients with low to average risk of colorectal cancer;
and 3) complete data to calculate sensitivity and speciﬁcity.
Exclusion criteria were: 1) non-peer reviewed articles; 2) any
articles whose primary aim was not to assess colorectal cancer
screening; 3) articles not in English or French; 4) articles pub-
lished prior to 1975; and 5) high risk screening populations. 
Heterogeneity within screening test groups was evaluated using
X2 test. Combining diagnostic accuracy measures, a summary
operator-receiver curve (SROC) was constructed with sensitivity
(from pooled data) and speciﬁcity (from SROC) for each CRC
screening test. RESULTS: Initial literature search found 399 for
FOBT, 253 for DCBE, 394 for FSIG, 434 for COL, and 345 for
CTCOL. Of these, 12, 8, 10, 8, and 13 articles respectively, were
selected for inclusion in the ﬁnal analysis. COL is the only screen-
ing strategy without signiﬁcant heterogeneity among studies (p
= 0.078). Sensitivity and speciﬁcity for FOBT, DCBE, FSIG, COL
and CTCOL was 0.543 and 0.976, 0.760 and 0.990, 0.749 and
0.9998, 0.866 and 0.999, 0.867 and 0.972, respectively. CON-
CLUSIONS: Speciﬁcity of all screening tests is high with greater
variation evident in the sensitivity (0.54–0.87) estimates. COL
results are considered most reliable. Additional studies are
required to validate CTCOL results due to signiﬁcant hetero-
geneity. Positive FOBT, DCBE, FSIG and CTCOL results must
be further investigated with COL.
